Acitretin

Dublin, Aug. 12, 2021 (GLOBE NEWSWIRE) -- The "Netherton Syndrome Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. This 'Netherton Syndrome - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Netherton Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.Netherton Syndrome EpidemiologyThe Netherton Syndrome epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.Key FindingsThe disease epidemiology covered in the report provides historical and forecasted Netherton Syndrome epidemiology segmented as the prevalent population of Netherton Syndrome and severity-specific cases of Netherton Syndrome. The report includes the prevalent scenario of Netherton Syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.Country-wise Netherton Syndrome EpidemiologyThe epidemiology segment also provides the Netherton Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.The prevalent population of Netherton Syndrome in the 7MM countries was estimated to be 3,411 cases in 2020.Netherton Syndrome Drug ChaptersThe drug chapter segment of the Netherton Syndrome report encloses the detailed analysis of Netherton Syndrome marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps understand the Netherton Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.Over the past years, treatment options for NS have not evolved; current approaches are all limited to symptomatic relief or supportive care with marginal efficacy and undesirable side effects. A gentle/soft non-detergent liquid cleansing oil, preferably with an acidic pH (5) to counteract overactive serine proteases, is recommended for daily bath and/or shower. Liberal use of bland emollients along with topical corticosteroids and calcineurin inhibitors (tacrolimus and pimecrolimus) for inflammatory skin lesions is also advisable. However, topical corticosteroids carry a risk of increased systemic absorption due to skin barrier defects.Topical tacrolimus has shown efficacy in NS patients, with daily applications reducing erythema. However, their dose and frequency of use should be strictly monitored to avoid toxicity due to systemic absorption, additional barrier damage, or possible persistence of lesions. Oral acitretin has also been demonstrated to improve cutaneous lesions and foster hair growth in regions of alopecia associated with the disease. Furthermore, Narrowband UVB (NB-UVB) phototherapy and psoralen UVA therapy may improve the cutaneous lesion. The adverse effects of NB-UVB phototherapy have been linked to dose and frequency; while erythemal doses damage the barrier, suberythemal doses enhance barrier function and production of antimicrobial peptidesNetherton Syndrome Market OutlookThe Netherton Syndrome market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Netherton Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.This segment gives a thorough detail of Netherton Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.Due to the nature of the disease, over-the-counter (OTC) products like moisturizers and topical emollients are often used by patients either self-prescribed or at the discretion of the treating physician. The forecast, however, only considers active treatment being prescribed. The launch of the key assets (LM-030 and Imsidolimab) during the forecast period (2018-2030) would significantly fuel the market. Also, considering the high unmet needs prevailing the treatment, the willingness to pay for efficient treatment is high among the consumers, which will add to the market growth.Key FindingsThis section includes a glimpse of the Netherton Syndrome market in the 7MM. The market size of Netherton Syndrome in the seven major markets was USD 14.6 million in 2020.Netherton Syndrome Drugs UptakeThis section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2030. The analysis covers Netherton Syndrome market uptake by drugs, patient uptake by therapies, and drug sales.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.Netherton Syndrome Pipeline Development ActivitiesThe report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Netherton Syndrome key players involved in developing targeted therapeutics.Major players include Lifemax Laboratories and AnaptysBio, whose key products are expected to get launched in the US market by 20XX.Pipeline Development ActivitiesThe report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Netherton Syndrome emerging therapies.KOL ViewsTo keep up with current market trends, we take KOLs and SME's opinion working in the Netherton Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Netherton Syndrome market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.Competitive Intelligence AnalysisThe publisher performs a Competitive and Market Intelligence analysis of the Netherton Syndrome market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. Key Topics Covered: 1. Key Insights2. Report Introduction3. Netherton Syndrome Market Overview at a Glance3.1. Market Share (%) Distribution of Netherton Syndrome in 20183.2. Market Share (%) Distribution of Netherton Syndrome in 20304. Executive Summary of Netherton Syndrome5. Disease Background and Overview5.1. Introduction5.2. Clinical Manifestations5.3. Pathogenesis5.4. Diagnosis5.5. Treatment of Netherton Syndrome (NS)6. Epidemiology and Patient Population6.1. Key Findings6.2. 7MM Total Prevalent Population of Netherton Syndrome6.3. Epidemiology of Netherton Syndrome6.4. The United States6.5. EU56.5.1. Germany6.5.2. France6.5.3. Italy6.5.4. Spain6.5.5. United Kingdom6.6. Japan7. Organizations contributing toward the fight against NS8. Patient Journey 599. Case Study10. Emerging Drugs10.1. Key Cross: Emerging Therapies10.2. LM-030: Lifemax Laboratories10.3. Imsidolimab: AnaptysBio11. Other Assets11.1. Key Cross: Other Assets11.2. Ustekinumab: Janssen Biotech11.3. Secukinumab: Northwestern University11.4. Dupilumab: University Hospital12. Netherton Syndrome: 7 Major Market Analysis12.1. Key Findings12.2. Market Size of Netherton Syndrome in 7MM12.3. Market Outlook12.4. United States Market Size12.4.1. Total Market Size of Netherton Syndrome in the United States12.4.2. Market Size of Netherton Syndrome by Therapies in the United States12.5. EU-5 Market Size12.6. Germany12.7. France12.8. Italy12.9. Spain12.10. United Kingdom12.11. Japan 13. KOL Views14. Market Drivers15. Market Barrier16. SWOT Analysis17. Unmet Needs18. Appendix Companies Mentioned For more information about this report visit

SAN DIEGO and MILTON, Ontario, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI - News) ( ) and Stellar Pharmaceuticals Inc. ("Stellar Pharma") (OTCQB:SLXCF.PK - News) (OTCBB:SLXCF.PK - News) (Pink Sheets:SLXCF), a Canadian public company, announced today the signing of an exclusive license agreement. Under the agreement, Stellar Pharma has the exclusive right to sell Apricus Bio's MycoVa(TM) product for the treatment of onychomycosis (nail fungus) in Canada, following receipt of Canadian regulatory approval for such product. The exclusive license agreement provides for an upfront payment, regulatory approval milestone, sales achievement milestones and royalty payments during the term of the agreement. Onychomycosis is a chronic persistent fungal infection of the nail bed resulting in thickening and discoloration of the nail, which sometimes can be accompanied by serious pain and disability. According to the Merck Manual, the worldwide incidence rate of onychomycosis is approximately 10%. As described by Iorizzo and Piraccini (2007), the incidence has been increasing due to diabetes, immunosuppression and an aging population. While occurring in approximately 2.6% of children younger than 18 years, it occurs in as much as 90% of the elderly population (eMedicine.medscape.com). As of 2008, Thomson Reuters Pharma had stated that the worldwide market was approximately $2.8 billion in size and is expected to grow to approximately $2.9 billion by 2014. The advantage of Apricus Bio's MycoVa(TM) product is that it is easy to apply, and is therefore believed to improve patient compliance. MycoVa(TM) is applied to the infected nails, typically at bedtime, with minimal preparation, such as simply washing with soap and water. The formulation allows significant amounts of the drug to penetrate through the nail plate to the nail bed and surrounding area where fungus is located without significant systemic exposure. Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus Bio commented, "We are very pleased with our exclusive license agreement with Stellar Pharma and we look forward to the future commercialization in the Canadian market of MycoVa(TM), our second major product utilizing our proprietary NexACT(R) technology. We are very impressed with the experience of Rob Harris and his team at Stellar Pharma, and we are very excited about this first potential launch of this important drug in that market. We also hope that our partnership with Stellar Pharma will produce additional collaborations among multiple NexACT(R) products in the future." Rob Harris, President and Chief Executive Officer of Stellar Pharma stated, "We are excited about this opportunity and are very pleased to be able to strengthen our dermatology portfolio in Canada. I would like to thank Bassam and his excellent team at Apricus Bio for providing us with this opportunity to launch MycoVa(TM) in the Canadian market. We will be assisting Apricus Bio in the filing of a New Drug Submission for MycoVa(TM) for onychomycosis and look forward to its commercial launch in Canada following Canadian regulatory approval." About MycoVa(TM) MycoVa(TM) combines an existing, approved drug for nail fungus, terbinafine, with the NexACT(R) technology that enhances the absorption of the drug through the skin. In January 2011, the Company announced that an additional analysis showed that MycoVa(TM) is as effective for the treatment of nail fungus as the current European standard of care for topical therapy, Loceryl(R) (an ointment made by Galderma). In June 2011, the Company announced that based on a reanalysis of its Phase III trials for its MycoVa(TM) product for treating onychomycosis (nail fungus), it is revisiting its regulatory strategy for the drug and will seek guidance from regulatory authorities in the U.S., Canada and Europe. A combined post-hoc analysis of two randomized, double-blind, vehicle controlled, multicenter, parallel group Phase III studies to assess the efficacy, safety and tolerability of MycoVa(TM) demonstrated statistically significant results in primary and secondary efficacy endpoints in favor of active treatment in patients who did not present with comorbid tinea pedis (athlete's foot), as these patients are considered at higher risk of reinfection. About Apricus Biosciences, Inc. Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT(R) technology. Apricus Bio's current pipeline includes Vitaros(R), approved in Canada for the treatment of erectile dysfunction, Totect(R) the only drug approved in the US for the treatment of anthracycline extravasation, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare. The Company also expects to develop and/or acquire and then bring to market additional pharmaceutical products in areas of care that will benefit patient needs worldwide. For further information on Apricus Bio, visit and for information on its subsidiary please visit You can also receive information at and About Stellar Pharmaceuticals Inc. Stellar Pharma and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market. Stellar Pharma currently competes in the dermatology market in Canada with its promotion of Soriatane(R)* (acitretin). Stellar Pharma also markets Bezalip(R)* SR (bezafibrate), NeoVisc(R) (1.0% sodium hyaluronate solution) and Uracyst(R) (sodium chondroitin sulfate solution 2%) in the Canadian market place and is awaiting regulatory approval for Cambia(R)** (diclofenac potassium for oral solution) in Canada. Additionally, NeoVisc(R) and Uracyst(R) are commercially available in 58 countries and are sold globally through various international partnerships. Stellar Pharma is currently in negotiations to license both NeoVisc(R) and Uracyst(R) in the US and other international markets. For further information on Stellar Pharma, visit and for information on its subsidiary please visit Apricus Bio's Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to receive issued patents on its NexACT(R) technology and products, develop such patented technology into product candidates, have its Rx Division products and product candidates such as Vitaros(R) and MycoVa(TM) approved by relevant regulatory authorities and its Consumer Healthcare Division products either approved or cleared by relevant regulatory authorities or be in compliance with appropriate regulatory requirements, to successfully manufacture and commercialize such Rx Division products as Totect(R) for the treatment of anthracycline extravasation, Vitaros(R) for erectile dysfunction and MycoVa(TM) for onychomycosis in the U.S., Canada, and in other countries along with its Consumer Healthcare Division products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company. Stellar Pharmaceuticals' Forward Looking Statement This press release contains certain forward-looking statements about Stellar Pharma as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties, Stellar Pharma's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including general economic conditions, the ability of Stellar Pharma to successfully integrate operations, and the timing of expenditures and expansion opportunities, any of which could cause actual results to vary materially from current results or anticipated future results. See Stellar Pharma's reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. Stellar Pharma assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time. *Soriatane and Bezalip are registered trademarks and under license from Actavis Group PTC ehf **Cambia is a registered trademark and under license from Nautilus Neurosciences, Inc. Contact: Apricus Biosciences, Inc.Edward Cox, V.P.Corporate Development & Investor Relations, Apricus Bio, Inc.(858) 848-4249ecox@apricusbio.comApricus Bio Investor RelationsPaula SchwartzRx Communications Group, LLC(917) 322-2216pschwartz@rxir.comStellar Pharmaceuticals Inc.Attention: Scott LangilleCFO(519) 434-1540scott.langille@stellarpharma.comAttention: Arnold TenneyChairman705-445-9505